What Is the Role of Aspirin in Primary Prevention in Patients With Elevated Lp(a)?
View Full Paper
Ask AI
Bookmark
Share
Key result
Aspirin may reduce MACE in primary prevention patients with genetically elevated Lp(a) without excess bleeding.
Why the study?
Clinical equipoise exists regarding whether aspirin modifies Lp(a)-mediated atherothrombotic risk in primary prevention, as large primary prevention trials showing no net clinical benefit did not measure plasma Lp(a).
Does aspirin reduce major adverse cardiovascular events in adults with elevated Lp(a) in the primary prevention setting?
Population
Adults in primary prevention settings with elevated lipoprotein [Lp] or genetic variants associated with…
Comparison
Aspirin vs Placebo or no aspirin
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
No practice change for primary prevention aspirin; leaves open targeted benefit in genetically elevated Lp(a) pending prospective trials.
Structured PICO
Does aspirin reduce major adverse cardiovascular events in adults with elevated Lp(a) in the primary prevention setting?
P
Population
Adults in primary prevention settings with elevated lipoprotein(a) [Lp(a)] (>30 mg/dL or >75 nmol/L) or genetic variants associated with elevated Lp(a)
I
Intervention
Aspirin (e.g., 100 mg/day or 100 mg every other day)
C
Comparator
Placebo or no aspirin
O
Outcome
Major adverse cardiovascular events (MACE)composite
While aspirin lacks net benefit in general primary prevention, genetic data suggest it may abrogate the increased atherothrombotic risk in patients with elevated Lp(a), highlighting the need for prospective trials using plasma Lp(a) measurements.
Limitations
- Current evidence is limited to post-hoc genetic analyses rather than prospective trials measuring plasma Lp(a).
- LPA variants studied have a low prevalence of ~3-4% in the general population, mainly in subjects from Europe.
- Aspirin/LPA gene interactions are limited to genetic analyses rather than plasma Lp(a) levels
- LPA variants studied have low prevalence (~3-4%)
- Data mainly from subjects of European descent
- Post-hoc nature of the analyses
Cite This Study
Sotirios Tsimikas (2023) conducted a review in Elevated Lipoprotein(a). Aspirin vs. Placebo was evaluated. Post-hoc analyses suggest aspirin may reduce major adverse cardiovascular events in primary prevention patients with genetically elevated Lp(a) without significantly increasing bleeding risk.
Topics
View Full Paper
Ask AI
Bookmark
Share